Stocks Health care RDHL
NASDAQ · Health careRedHill Biopharma Ltd. (RDHL)
RedHill Biopharma Ltd. reported revenue of $8M in fiscal 2024, up 23.2% from a year earlier. It posted a net loss of $8.3M. In fiscal 2024 capital spending exceeded operating cash flow by $9.4M. At December 31, 2024 it held $4.6M in cash. Its latest periodic report to the SEC is the annual report (foreign issuer) (20-F) filed on April 27, 2026.
Watch RDHL in 60 secondsWhat RedHill Biopharma Ltd. does
RedHill Biopharma Ltd. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker RDHL.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2024 | $8M | -$8.3M | $0.00 | -$9.4M |
| 2023 | $6.5M | $23.9M | $0.01 | -$35.8M |
| 2022 | $61.8M | -$71.7M | -$0.12 | -$29.4M |
| 2021 | $85.8M | -$97.7M | -$0.21 | -$65.2M |
| 2020 | $64.4M | -$76.2M | -$0.21 | -$49M |
| 2019 | $6.3M | -$42.3M | -$0.14 | -$40.9M |
Full financial statements: income, balance sheet and cash flow
Where RDHL ranks in Health care
Latest SEC filings
What RedHill Biopharma Ltd. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 1, 2026
- August 31, 2026
- August 7, 2026
- August 6, 2026
- July 28, 2026
- July 14, 2026
- July 2, 2026Form F-3 filing F-3
- July 1, 2026
- June 29, 2026
- June 29, 2026
Insider trades
What the people running RedHill Biopharma Ltd. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $1.4K worth of shares in the last 90 days and bought none on the open market.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| July 10, 2026 | Raday GileadChief Operating Officer | Sold | 14,130,000 | $1.4K |
Who owns RDHL
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
Largest institutional holders
Insiders
1 insiders reported holding 218,780,000 shares in total, about $109.4M at the last price.
| Holder | Shares |
|---|---|
| Raday GileadChief Operating Officer | 218,780,000 |
Questions about RDHL
What does RedHill Biopharma Ltd. do?
RedHill Biopharma Ltd. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker RDHL.
Is RedHill Biopharma Ltd. profitable?
No. In fiscal 2024 it reported a net loss of $8.3M on revenue of $8M.
How much revenue does RedHill Biopharma Ltd. make?
In fiscal 2024 RedHill Biopharma Ltd. reported revenue of $8M. That is 23.2% more than a year earlier.
When did RedHill Biopharma Ltd. last report?
Its most recent periodic report is the annual report (foreign issuer) (20-F) filed on April 27, 2026. It covers the period to December 31, 2025. Its newest filing of any kind is the foreign issuer update from September 1, 2026.
Similar companies
Compare RDHL with
Follow RDHL
Get an email when RedHill Biopharma Ltd. files with the SEC: results, executive changes, material agreements and annual reports.
Follow RDHL: get an email when it filesWhere the numbers come from
Financial figures are the values RedHill Biopharma Ltd. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.